HighTower Advisors
CERE

HighTower Advisors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

HighTower Advisors’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-57,988
Closed -$2.36M – 4042
2024
Q2 		$2.36M Sell
57,988
-4,088
-7% -$170K ﹤0.01% 1357
2024
Q1 		$2.62M Sell
62,076
-1,000
-2% -$42K ﹤0.01% 1297
2023
Q4 		$2.66M Sell
63,076
-11,212
-15% -$322K ﹤0.01% 1282
2023
Q3 		$1.63M Buy
74,288
+250
+0.3% +$6.26K ﹤0.01% 1484
2023
Q2 		$2.36M Sell
74,038
-500
-0.7% -$15.3K ﹤0.01% 1256
2023
Q1 		$1.81M Sell
74,538
-500
-0.7% -$14.7K ﹤0.01% 1345
2022
Q4 		$2.38M Sell
75,038
-30
-0% -$847 0.01% 1196
2022
Q3 		$2.12M Sell
75,068
-500
-0.7% -$14.9K 0.01% 1201
2022
Q2 		$1.99M Sell
75,568
-600
-0.8% -$17K 0.01% 1257
2022
Q1 		$2.69M Buy
76,168
+2,680
+4% +$78.3K 0.01% 1207
2021
Q4 		$2.37M Buy
73,488
+1,644
+2% +$58K 0.01% 1266
2021
Q3 		$2.13M Hold
71,844
– – 0.01% 1214
2021
Q2 		$1.85M Buy
71,844
+5,300
+8% +$75.9K 0.01% 1267
2021
Q1 		$914K Buy
66,544
+21,219
+47% +$310K ﹤0.01% 1625
2020
Q4 		$752K Buy
+45,325
New +$589K ﹤0.01% 1421

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

HighTower Advisors's CERE Position: Q3 2024 in Review

HighTower Advisors sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 57,988 shares — an estimated $2.36M sold.

HighTower Advisors first reported a position in CERE in Q4 2020 and held it in 15 quarters. The position peaked at $2.69M in Q1 2022. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • HighTower Advisors reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • HighTower Advisors sold 57,988 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $2.36M.
  • HighTower Advisors first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 15 quarters.
  • HighTower Advisors's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $2.69M in Q1 2022.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on HighTower Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.